.png?width=1800&height=600&name=MicrosoftTeams-image%20(82).png)
2 min read
Geneva, Switzerland, and Menlo Park, CA, December 17, 2018 – Selexis SA and Teneobio, Inc. announced today that they have entered into a second…
2 min read
Effort Designed to Safely and Efficiently Speed Drug Candidates into the Clinic
3 min read
As a child growing up in Nigeria, I had first-hand experience of the suffering caused by debilitating diseases such as malaria. This fueled my…
2 min read
Selexis SUREtechnology Platform™ Successfully Expresses Hoba’s HB-086 in CHO Cells
3 min read
The CEOs of Selexis SA and KBI Biopharma Answer Some Common Questions (An interview from BIO 2018) Selexis CEO Igor Fisch, PhD, and KBI Biopharma…
2 min read
Geneva, Switzerland, 10 July 2018 – Selexis SA today announced that under the terms of an earlier commercial license agreement, Symphogen A/S has…
3 min read
Program is on track for clinical trial start in H2 2019
2 min read
Company Among Five 2018 Laureates Recognized for Important, Sustainable Contributions to the Biotech Industry in Switzerland
1 min read
In 2001, I co-founded Selexis with prize money that I won from the de Vigier Foundation in Switzerland followed by the NETS prize (the predecessor…
2 min read
Company’s Growth Momentum Continues Following Signing of 100th Commercial License Agreement
